CytoSorbents, Inc
17
3
3
6
Key Highlights
Risk & Performance
Pipeline Risk Assessment
Pipeline Risk Assessment
Based on historical performance
High Risk
Score: 80/100
29.4%
5 terminated/withdrawn out of 17 trials
54.5%
-32.0% vs industry average
6%
1 trials in Phase 3/4
100%
6 of 6 completed trials have results
Key Signals
Enrollment Performance
Analytics
Activity Timeline
Global Presence
Clinical Trials (17)
CytOSorb TreatMent Of Critically Ill PatientS Registry
Role: lead
Safe and Timely Antithrombotic Removal (STAR) Registry
Role: lead
Safe and Timely Antithrombotic Removal - Direct Oral Anticoagulants Apixaban & Rivaroxaban (STAR-D)
Role: lead
Safe and Timely Antithrombotic Removal - Ticagrelor (STAR-T)
Role: lead
Hemoadsorption for Prevention of Vasodilatory Shock in Cardiac Surgery Patients With Infective Endocarditis
Role: collaborator
CytoSorb® Reduction of FREee Hemoglobin/Acute Kidney Injury (AKI) During Cardiac Surgery
Role: lead
Role of Cytosorb in Left Ventricular Assist Device Implantation
Role: collaborator
Registry of CytoSorb Therapy in COVID-19 ICU Patients
Role: lead
Extracorporeal Therapy for the Removal of Myoglobin Using the CytoSorb in Patients With Rhabdomyolysis
Role: lead
Adjuvant Therapy With CytoSorb in Refractory Septic Shock
Role: collaborator
Extracorporeal Elimination of Cytokines Following Abdominal-thoracic Esophagectomy
Role: collaborator
Ticagrelor CytoSorb Hemoadsorption
Role: lead
Does Whole Blood Adsorber During CPB Reduce Vasoactive Drugs Postoperatively in Endocarditis Patients Undergoing Valve Surgery?
Role: collaborator
CytoSorb Reduction of Free Hemoglobin During Cardiac Surgery
Role: lead
Extracorporeal Cytokine Adsorption as Additive Treatment of CAR-T Associated Cytokine Release Syndrome (CRS)
Role: collaborator
Removal of Cytokines in Patients Undergoing Cardiac Surgery With CPB
Role: collaborator
Cytokine Removal in Cardiopulmonary Bypass Patients
Role: collaborator
All 17 trials loaded